Navigation Links
Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:3/1/2012

SAN DIEGO, March 1, 2012 /PRNewswire/ -- Receptos Inc. today announced that the company is scheduled to present at the Cowen and Company 32nd Annual Health Care Conference at noon EST on Wednesday, March 7, 2012, at the Boston Marriott Copley Place in Boston, Massachusetts. Faheem Hasnain, president and chief executive officer, will provide an overview of the company and an update about its clinical development programs.

"This is an exciting time at Receptos as we move forward with plans to initiate multiple Phase 2 clinical trials later this year and to close our Series B financing round," Hasnain said. "This presentation at the Cowen and Company Health Care Conference gives us the opportunity to provide an update about these initiatives, as well as other areas of focus for Receptos."

About RPC1063 and S1P1 Agonists
RPC1063, developed in the labs of Receptos, is a novel, highly selective S1P1 agonist exhibiting picomolar potency that is effective in rodent models of multiple sclerosis, and possesses an excellent safety profile in non-clinical toxicology studies. In addition to selectivity, which reduces the likelihood of "off-target" side effects, RPC1063 has an appropriately short half-life to promote rapid reversibility of lymphopenia. S1P1 is a G protein-coupled receptor (GPCR) that binds the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P is a circulating lipid that binds to five GPCRs termed S1P1-5. S1P1 selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. In the disease state of multiple sclerosis, S1P1 agonism works by selectively sequestering circulating lymphocytes, blunting the underlying autoimmune cause of multiple sclerosis.

About Receptos
Receptos is a biopharmaceutical company developing autoimmune therapeutic candidates through information‐driven drug discovery, inclu
'/>"/>

SOURCE Receptos Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Receptos Scientists Publish Determination of a High Resolution Sphingosine 1-Phosphate Receptor 1 Structure in Science
2. Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research
3. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
4. Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
5. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
6. Regeneron Announces March 2012 Investor Conference Presentations
7. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
8. OncoSec to Present at 10th Annual BioPartnering North America
9. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
10. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
11. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... CA (PRWEB) June 18, 2013 (PRWEB) June 18, ... #1 time and attendance system in North America, ... that shares employee data and payroll records between ... AccountLinx Plus automates ExakTime software setup and ... software imports employee data from a business’ current ...
(Date:6/18/2013)... Miami, FL (PRWEB) June 18, 2013 The ... associate the skin as an important human body part. Similar ... cared for in order to function, repair and grow. Recent ... with vitamins and supplements, is just as important as other ... and supplements to aid in skin cell reproduction, increase the ...
(Date:6/18/2013)... RegeneCure announced today the start of ... Regeneration (GBR) Dental Membrane as a bone stimulating aid for ... when patients have a tooth replaced with a dental implant ... implant. Consequently there is often a need to support the ... The bone substitute material, in turn, needs to be held ...
(Date:6/18/2013)... 2013 Edison Investment ... announces the initiation of full coverage of ... developing and marketing products for orphan oncology ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison has ... investment merits of BioAlliance Pharma, focusing in ...
Breaking Biology Technology:ExakTime Introduces AccountLinx Plus 2Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3
... March 18 Ingenuity Systems, the,leading provider ... has,announced that they have extended and expanded ... to Ingenuity Pathways Analysis,(IPA) software. The new ... to researchers for rapid assessment of the ...
... engineer genetic modifications, thereby providing scientists with a ... food production to drug discovery. However, this sophisticated ... threat of engineered pathogens. New research published in ... that computational tools could become a vital resource ...
... New Monograph Strengthens Safety Nets to Prevent Serious Health ... ... 17 The U.S. Pharmacopeial (USP),Convention today announced a ... official compendium of the United States. The,revision strengthens safety ...
Cached Biology Technology:Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline 2On the trail of rogue genetically modified pathogens 2USP Announces Revised Glycerin Monograph 2USP Announces Revised Glycerin Monograph 3
(Date:6/19/2013)... for human consumption qualifies as a gluten-free cereal that ... scientists have confirmed in a study published in ACS, ... , Joyce Irene Boye and colleagues point out that ... alone have CD. They develop gastrointestinal and other symptoms ... contain gluten-related proteins. Boye,s team sought to expand dietary ...
(Date:6/19/2013)... fall 2012, the European Medicines Agency (EMA) approved ... first ever gene therapy for clinical use in ... had developed AAV-LPL S447X for the treatment of ... deficiency (LPLD) which affects approximately one or two ... severe, life-threatening inflammations of the pancreas. Afflicted individuals ...
(Date:6/18/2013)... A UT Arlington environmental engineer has been awarded ... District to ensure water quality and flow in ... Project. , Andrew Kruzic, UT Arlington associate professor ... and locations to add monochloramine to the water ... the new pump stations and pipelines. Adding monochloramine ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2
... -- The number of overweight and obese Americans continues to ... up to 20 percent are obese. While the number of ... increase of overweight infants -- individuals under 11 months old ... pregnant women who are overweight/obese are more likely to give ...
... Elsevier announced today that it is launching a ... Engineering. The journal will be published bimonthly, and will ... of natural gas science and engineering. The first issue ... Natural Gas Science and Engineering will cover the fields ...
... Ohio State University have found that the number of copies ... cancer in a mouse model. Publishing in the Jan. 3 ... or Down syndrome in humans, can repress tumor growth. ... whether people with Down syndrome develop cancer less often than ...
Cached Biology News:Mom's obesity during conception phase may set the stage for offspring's obesity risk 2Mom's obesity during conception phase may set the stage for offspring's obesity risk 3Mom's obesity during conception phase may set the stage for offspring's obesity risk 4Elsevier launches new journal: Journal of Natural Gas Science and Engineering 2Gene dose affects tumor growth 2
Immunogen: Purified native p24 from strain IIIB. Storage: -20 C, Avoid Freeze/Thaw Cycles...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Request Info...
... epitope is specific for Kir2.1 and ... known protein.,SPECIES REACTIVITIES: The immunogen ... porcine and guinea pig. It is ... (17/19 residues) and chick (15/19 residues). ...
Biology Products: